Don't Miss Any Side.
Published loading...Updated

Roche's 5-Year Study Reveals Game-Changing Results for Rare Disease Treatments

Summary by stocktitan.net
New long-term data shows sustained motor function improvements for Evrysdi and Elevidys in treating SMA and Duchenne. Key findings reveal 99% adherence rate and disease progression slowdown.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

stocktitan.net broke the news in on Monday, March 17, 2025.
Sources are mostly out of (0)